PARIMA grows duck cells as an undifferentiated biomass suspended in liquid. Its process skips scaffolds, microcarriers and tissue maturation, tasks that enter other production methods when cells need a surface to grow on or a manufacturer wants to build structured tissue.
On 2 July 2026, the company reported a multi-tonne run on Vow’s 22,000-litre production line in Sydney. It also reported a 99% reduction in production cost against its own earlier runs and described the economics as viable. The announcement gives that relative reduction without an exact saleable output, a cost per kilogram or a series of repeated runs. PARIMA’s production announcement.
The choice of food reaches back into the factory. A producer growing biomass can concentrate on expanding the culture and harvesting it. A producer developing a steak also has to arrange tissue into the structure the customer expects to eat. Both work with animal cells. They give the production line different jobs.
That helps explain why cultivated meat is reaching the market through such varied products. Companies have served customers and obtained clearances for particular foods. Some are developing premium cuts or seafood. Others are putting a small cultivated fraction into a hybrid recipe or supplying fat as an ingredient. Each route joins a production process to a customer who can pay for what it makes.
A batch starts well before the production tank
Cultivated meat begins with animal cells selected for growth outside the animal. Depending on the process, developers may use muscle progenitor cells, stem-like cells, fibroblasts, fat cells or another suitable population. They characterise the cells and establish a cell bank. Later batches can then start with a controlled, traceable source.
The first culture is small. Operators expand it through a seed train, feeding progressively larger vessels until they have enough cells to start the production run. Throughout that sequence, the cells need water, amino acids, carbohydrates, vitamins and salts, along with the growth-supporting inputs required by the particular cell line. The culture medium supplies those ingredients. GFI’s technical overview.
Commercial developers have spent years working on serum-free media. Early research often used fetal bovine serum, which is costly, varies between batches and brings animal-derived material into a process intended to reduce reliance on livestock. Removing it requires a formulation that still supports reliable growth. Animal-component-free formulations go further by replacing other animal-derived inputs too.
Once the cells have multiplied, the next step depends on the food. A manufacturer can harvest biomass for a minced or processed product. Another may encourage cells to differentiate into muscle or fat. Producing a structured cut adds the task of arranging tissue in three dimensions, using an edible scaffold or another method that gives cells a place to grow.
Harvesting brings the material back into more familiar food manufacturing. It may be washed, processed, blended with other ingredients and formed into a finished recipe. The product on the plate could contain cultivated fat, plant protein, a fermentation-derived ingredient and conventional seasonings.
Plant-based meat gets its structure and flavour from plant ingredients. Precision fermentation uses microorganisms to make a particular protein, fat or other ingredient. Cultivation grows animal cells. Manufacturers can combine these methods, and the proportions affect both the eating experience and the cost of the food.
A pâté can use harvested material that will be blended and formed. A fat ingredient has to perform in someone else's recipe. A whole-cut steak adds a three-dimensional structure to grow and maintain. The label “cultivated meat” includes all of them. Regulators and producers also use cell-cultivated, cultured and cell-based food. “Lab-grown meat” came from the early setting; much of the work now takes place in food-manufacturing facilities.
The vessel has to fit a production schedule
Animal cells have long been grown in biomedical research. Moving the process into food production puts much tighter pressure on the cost of each kilogram. A food manufacturer also has to repeat the run often enough to cover the facility, staff and equipment.
Animal cells are more fragile than yeast or bacteria. Mixing can damage them through shear stress. Oxygen, pH, temperature and nutrient supply have to stay within the range the culture can tolerate. At larger volumes, operators must move oxygen into the liquid, remove carbon dioxide and metabolic waste, and keep conditions sufficiently even throughout the vessel.
A process that performs well in a small research vessel can behave differently in a production tank. The geometry changes. So do mixing and mass transfer, the movement of gases and dissolved substances through the culture. Higher cell density can improve output per litre while making oxygen delivery more demanding. Engineers have to find conditions that work together over the whole run.
Once cell growth is finished, the vessel still has work around it. The culture must be harvested, and the equipment has to be cleaned, sterilised and checked before the next run. If harvesting holds up that sequence, the production tank can spend time waiting even while the cell-growth process performs well.
The production schedule follows the culture through those operations. Some harvested material may be lost during processing or fall outside the food's specification. A delivery commitment draws on the saleable amount, the time until another batch is ready and the share of runs that reach that point. The same nominal vessel size can support different amounts of food over a month.
Contamination makes the connection especially clear. Animal cells grow more slowly than many bacteria, and nutrient-rich media can support both. Contamination in a research vessel costs an experiment. In a production line, it can cost a production cycle whose media, labour and facility time have already been paid for.
Manufacturers use environmental monitoring, closed transfers, filtered air, cleaning-in-place, sterilisation-in-place and hygienic equipment design to manage that risk. Prevention occupies staff, equipment and part of the schedule. A failed culture consumes another part, with the media and labour already spent. Both enter the cost of the food that eventually ships.
Pharmaceutical aseptic manufacturing offers extensive experience with animal cells. Food producers can draw on that experience while developing controls for products with much lower selling prices per kilogram. Equipment design and process validation become part of the same manufacturing task as growing the cells.
The medium has to fit the food’s selling price
Culture media can account for a large part of operating cost. A formulation designed for research or pharmaceutical production may include ingredients whose price makes sense in those settings. A food factory needs safe nutrients available in volume at much lower cost.
Several routes are being tested. Producers can use food-grade ingredients where suitable, reduce their reliance on expensive recombinant growth factors or develop cells that need fewer supplements. Plant-derived hydrolysates offer another nutrient source. More efficient use of the medium, including recycling where feasible, can also reduce consumption. Fermentation suppliers may help bring down the price of particular growth-supporting ingredients.
A cheaper formulation that slows growth could occupy the vessel for longer. Raising cell density could produce more biomass and make harvesting more demanding. The effect of a media change can travel through the whole cycle, altering how much food the line produces before the next culture starts. Engineers have to follow it through growth and collection to establish the resulting cost.
This brings suppliers into the competitive picture. Media producers, fermentation companies, bioreactor manufacturers and scaffold developers influence the cost and reliability of the finished food. A cultivated-meat brand may depend on several businesses that consumers never see. Lower-cost inputs and shared production infrastructure could allow a company to expand with less capital tied up in its own equipment.
Techno-economic analyses give researchers a way to explore these choices. They estimate costs using assumptions about cell density, growth rate, media prices, reactor volume, energy, utilisation and yield. Changing an assumption can show which part of the process deserves more development work. Goodwin, Aimutis and Shirwaiker’s 2024 review.
For example, an assumed faster-growing cell line can shorten the growth stage in a model, allowing more runs over a year. A lower media price reduces the estimated cost of each run. Those are possible operating conditions. As measured factory results become available, replacing the assumed growth rate and input price changes the estimate and shows which part of the proposed process still needs development.
On 5 August 2013, Mark Post’s team presented a cultivated beef burger in London that reportedly cost about €250,000 to make. That proof-of-concept prototype showed that the food could be produced. Subsequent work on cells, media and equipment has taken the field into much larger vessels and commercial recipes. The historical prototype cost describes that early achievement; present production economics depend on the process and quantities a factory runs today. Mosa Meat’s account of the prototype cost.
The recipe opens a route to market
Commodity chicken is an unforgiving starting market. Conventional poultry production is efficient, its supply chains are established, and buyers expect a low price. An early cultivated product entering that market has little room to recover the cost of developing a new production process.
Premium foods can offer more room. Foie-gras-style products, high-grade tuna, salmon, speciality fats and premium beef may command prices that support early manufacturing costs. Buyers in those markets may also value animal welfare, traceability or supply consistency. The recipe and sales channel matter as much as the species.
GOOD Meat's Singapore retail product contained 3% cultivated chicken, combined with plant ingredients. In its 2024 announcement, the company said the formulation helped bring down cost, with sales planned through the rest of that year. Customers could buy the food and cook it at home. GOOD Meat’s retail announcement.
Most of that recipe came from other ingredients. A small cultivated fraction gave the company a way to sell a finished food while limiting how much cell-derived material went into it. Changing that fraction would change the quantities the cultivation process had to supply. Formulation and biomass production were working on the same commercial problem.
Fat contributes flavour, aroma and juiciness, so a relatively small quantity can change a plant-protein recipe. An ingredient producer can work on that contribution while a food manufacturer combines it with the rest of the product. Mission Barns has pursued cultivated pork fat. Mosa Meat has taken a regulatory route for cultivated bovine fat. Selling an ingredient also changes the customer. The company needs a manufacturer that can use it in a recipe and order it again.
Wildtype’s cultivated coho salmon has reached selected US restaurant settings, documented in the company’s launch announcements. Premium sushi and other high-value seafood dishes may accommodate a higher price than commodity poultry. Seafood buyers also have concerns about mercury, parasites, overfishing and pressure on marine ecosystems. Cultivation gives developers control over the growth setting. Claims about a particular food's composition or environmental effects still depend on its testing and assessment.
Vow has concentrated on unusual species and dining products, including cell-cultured quail. Aleph Farms has worked on structured beef, including its thin-cut steak. Their intended customers can pay for a more specialised food, giving manufacturers room to develop a process that would struggle at commodity chicken prices.
A restaurant works with a recipe, handling method and presentation chosen for its setting. Retail puts the food into customers' kitchens and introduces replenishment across shops. Expanding into that channel can change the amount a manufacturer has to produce and the price it has to support. Distribution becomes another part of the production plan.
Whole cuts add a further engineering task. A conventional steak contains aligned muscle fibres, connective tissue, fat and water in a three-dimensional structure. Blood vessels deliver oxygen and nutrients to growing tissue and remove waste. Cultivated tissue has to receive that supply through the production system. As it thickens, cells deep inside can run short of oxygen if diffusion alone carries it.
Researchers have investigated edible scaffolds, channels and perfusion to help feed the tissue. Materials under study include collagen, gelatin, alginate, cellulose, plant proteins, fungal materials and hydrogels. Extrusion, freeze-drying, electrospinning and 3D bioprinting offer ways to form structures. Each method adds a material or operation to the production route. Making that route affordable involves the speed of tissue formation, the price of its inputs and the consistency of the resulting cut. GFI’s overview of scaffolding and tissue structure.
Mince, pâté, fat, seafood-style products and hybrids give manufacturers routes with fewer structural requirements. Thick steaks involve more of the tissue-building work. A company selecting its first product is also selecting which of those operations it will develop and finance first.
Food review is happening product by product
Singapore authorised GOOD Meat's cultivated chicken in 2020. The regulatory record has since expanded to more species, recipes and production processes. A manufacturer choosing where to launch has to match its food to the route available in that market. GOOD Meat’s account of its first authorisation.
PARIMA announced Singapore clearances for cultivated chicken in October 2025 and cultivated duck in April 2026. SFA's register dates the clearance of Aleph Farms' Cultivated Thin-Cut Steak to 22 July 2026. PARIMA’s announcement, SFA’s approved-food register.
In the United States, FDA’s voluntary pre-market consultation examines a company’s cell-culture process and safety conclusion. It covers the cell line, manufacturing controls and inputs for the particular submission. A completed consultation can result in FDA stating that it has no further questions at that time about the company’s safety conclusion. The response applies to that submitted material and process.
FDA and USDA divide oversight according to the species and stage of production. FDA oversees cell collection, banking, growth and differentiation. For livestock and poultry products under USDA jurisdiction, oversight moves to USDA at harvest and continues through processing, inspection and labelling. FDA retains jurisdiction over other relevant products, including most seafood. Manufacturers need to follow the pathway for the food they intend to make. FDA’s regulatory overview.
Publicly documented FDA consultations have included UPSIDE Foods and GOOD Meat for chicken, Mission Barns for pork fat, Wildtype for coho salmon and Believer Meats for chicken. FDA’s consultation inventory and supporting records.
The US market also has state restrictions. Florida’s statute prohibits manufacturing cultivated meat for sale, selling it and distributing it in the state. A company that has completed the relevant federal steps still has to consider its intended sales destination. Political barriers can narrow the market available to a factory. Florida Statutes, section 500.452.
Mission Barns reached federal milestones for its pork fat and announced retail plans. Its ingredient strategy joins the production and regulatory work around pork fat to a finished recipe.
Australia and New Zealand approved Vow's cell-cultured quail as a novel food in 2025, with conditions covering composition, production and labelling. The product's premium dining route can accommodate early production costs while Vow develops supply in those markets. FSANZ’s A1269 approval materials.
The EU route remains in progress. Cultivated foods require authorisation under the Novel Food framework. Public applications include Gourmey’s cultivated duck cells for foie-gras-style products and Mosa Meat’s cultivated bovine fat. Both point toward markets where a specialised product or ingredient could support early production costs.
The UK is developing its own review framework. The Food Standards Agency and Food Standards Scotland’s cell-cultivated products sandbox runs from February 2025 to February 2027. Guidance published during 2026 addresses cell-line identity, production processes, microbiological hazards, hygiene and application requirements. It helps manufacturers understand the evidence expected in a safety review. FSA/FSS’s July guidance announcement, September authorisation guidance.
UK applications include cultivated bovine fat for human food, as documented in Mosa Meat’s UK submission announcement. Pet-food pathways moved earlier, under the rules for animal feed. A manufacturer seeking to supply food for people still needs the applicable human-food authorisation.
The Netherlands allowed controlled tastings of cultivated meat and seafood before full EU market authorisation, subject to safety conditions and a code of practice. Government records describe an initial pilot from January 2024 to January 2026. A letter to parliament dated 28 September 2026 addresses extending that pilot and includes a revised code and an evaluation of the earlier tastings. The programme gives developers experience with food and tasters under defined conditions. Government letter and supporting documents.
Israel has contributed research and commercial development, particularly through Aleph Farms. The company announced its cultivated-beef milestone in January 2024, describing a Ministry of Health “No Questions” letter issued the previous December. Aleph Farms’ regulatory announcement.
Choosing a launch market puts a review timeline into the factory's financial plan. Equipment and staff need financing while the application moves through the relevant process. A product designed for premium dining, a fat ingredient and a hybrid chicken recipe enter that calculation with different production needs and intended customers.
Safety follows the cells through the process
Food-safety review examines the cell line, medium, manufacturing steps, contaminants, residual inputs, composition, allergenicity and intended use. The finished recipe is part of that assessment. A cultivated-fat ingredient blended with plant protein can present a different nutritional and allergen profile from a food made mostly of cultivated cells.
FAO and WHO have reviewed hazards associated with cell-based foods. Their review includes hazards familiar to food manufacturers, such as microbial contamination, chemical residues and allergens, alongside the controls needed for cell culture. Regulators use the details of each product and process to assess these issues. FAO/WHO’s food-safety report.
Cultivation could reduce contamination routes associated with slaughter and carcass handling. It also puts more responsibility on the production system that grows and transfers the cells. Aseptic equipment, environmental monitoring, cleaning, sterilisation and closed transfers can help keep the culture under control. Those practices connect the safety of the food to the reliability of the production run.
Commercial developers generally aim to avoid routine antibiotics. Using them can mask contamination, leaving the underlying failure in place. Hygienic design and validated process controls address that failure. The regulatory submission documents the inputs used in the particular process under review.
Developers can use primary cells, naturally selected populations or non-engineered lines. Other processes may use genetic engineering to improve growth, stability, nutrient use or differentiation. The GMO status of the food depends on that specific line and method, with regulatory treatment varying by jurisdiction.
Nutritional composition varies with species, cell type, media, differentiation and recipe. A hybrid burger’s plant ingredients may add fibre; its seasonings may add sodium. Fat content and fatty-acid composition depend on what the manufacturer grows and blends. Micronutrients and allergens need to be assessed in the resulting food.
Growing and blending particular cells could eventually give manufacturers closer control over some nutritional characteristics. Any resulting nutritional claim belongs to the defined recipe and its measured composition. Adding plant ingredients or changing the fat fraction also changes the food that has to be assessed.
The environmental calculation runs through the factory
Growing animal cells for food could reduce the land used for grazing and feed, since the process produces the intended material directly. Some production scenarios also suggest lower water use. The climate calculation involves more variables.
A cultivated-meat facility needs electricity, heating and cooling. Its medium has to be manufactured, transported and, where required, purified. Equipment utilisation affects how those inputs are divided over the kilograms sold. A lightly used facility carries more operating and capital burden per unit than one running reliably near its intended schedule.
Life-cycle models can estimate substantial greenhouse-gas reductions against beef when they assume food-grade inputs and low-carbon energy. Scenarios using highly purified pharmaceutical-style ingredients or carbon-intensive power can perform much worse. The conventional meat chosen for comparison changes the result too. The 2025 cultivated-meat LCA guidelines compare these modelling choices and evidence gaps.
Purification is one point where the manufacturing choice enters the environmental calculation. Reducing the purification required for a safe input can change its upstream burden. Improving utilisation divides facility inputs over more food. As factories accumulate operating data, measured consumption can replace assumptions about those operations. The product, energy supply and conventional-meat comparator remain part of the calculation.
Media consumption, energy use, saleable yield and failed batches affect both the environmental and financial calculations. A failed culture has consumed nutrients and energy before producing saleable food. Reducing those losses can therefore improve both measures. A cheaper input can have a different environmental burden, so a cost saving alone leaves that effect unresolved. The two calculations have to describe the same product and production route to follow it.
Patents show which parts of production companies are developing
The cultivated-meat industry extends beyond the brands serving food. Patent activity includes work on cells, media and equipment by universities, research organisations and suppliers. It can reveal technical competition that a list of consumer-facing startups would miss.
Patent analyses by the Good Food Institute’s Asia-Pacific operation have documented Chinese filings across cell lines, culture media, bioprocessing and tissue engineering, including work by universities, research organisations and companies. A market map centred on US, Israeli and European food brands would miss those records. China’s biotechnology and fermentation-manufacturing base could also supply equipment and inputs as production expands. GFI APAC’s patent analysis.
The work starts with cell lines and ways to maintain them, serum-free and animal-component-free media, and growth-factor formulations. Microcarriers and cell-attachment systems support processes that need a surface; suspension-culture methods address cells growing in liquid. Equipment work covers bioreactor geometry, fluid handling, oxygenation and mass transfer. Tissue development brings in edible scaffolds, hydrogels, structured tissue formation and co-culture of fat and muscle. Harvesting, downstream processing, food formulation and texture carry that work into a finished product.
Four publications take us to different parts of the process. Mosa Meat's WO2023003470A1 concerns serum-free media for producing adipocytes, the cells that store fat. Aleph Farms' US20230407224A1 describes a multi-scaffold cell-cultivation system. UPSIDE Foods' US11891596B2 concerns cultivation in a filter cake. Mission Barns' US20230100306A1 describes scalable bioreactor systems.
The company names put these records in one industry. The documents spread the work across nutrients, cell support and equipment. A competitor map built around those tasks can include media suppliers and reactor developers alongside the food brands. The filings describe approaches the companies have sought to protect; their use in a particular operating facility requires its own documentation.
The unit counted in a patent map needs care. One invention can generate publications in several jurisdictions. Grouping them into patent families gives a clearer view of distinct inventions and the countries in which protection was sought.
The claims and current status at the relevant patent offices determine the scope of the rights. Those checks are necessary for conclusions about enforceability or freedom to operate in a particular jurisdiction. The production map above describes the subjects of the publications.
A factory commits money before it earns it
In the early 2020s, cultivated-meat companies attracted venture capital while much of their manufacturing history was still ahead of them. The funding environment subsequently tightened. GFI’s analysis records $73.9 million raised by cultivated-meat and seafood companies in 2025, down from $144 million in 2024. Its report describes investors placing more weight on cost, taste and scale. GFI’s 2025 industry report.
The sector saw closures and restructurings as well as continued technical work. Believer Meats advanced cultivated chicken through FDA review and built a large facility in North Carolina before its closure was reported in December 2025. Agronomics announced Meatable’s wind-down on 19 December 2025 after it failed to secure continued funding. Other businesses cut staff, changed products, merged or shifted toward licensing. Reporting on Believer’s closure, Agronomics’ Meatable announcement.
A large facility fixes part of the spending before the cell line, medium and production process have finished improving. It needs enough saleable output to pay for that commitment. If regulatory review or commercial launch takes longer than planned, the company has to finance more of the waiting period. Even an engineering success can leave a business short of cash at that point.
Staged expansion can give manufacturers time to learn before making the next capital commitment. Contract infrastructure and technology licensing offer other routes. Modular plants may let a company add capacity as the process and demand become clearer. Each option has costs of its own, including dependence on partners or limits on control, but it changes how much money must be committed upfront.
PARIMA’s use of Vow’s production line is an example of collaboration on existing infrastructure. More specialised suppliers and shared facilities could let companies concentrate on the part of the process they do best. A viable business might develop a cell line or supply media without also owning a food brand and every production asset.
Aleph Farms’ premium structured beef and Wildtype’s seafood give food brands differentiated products to sell. Vow has explored novel species and dining products. Hybrid foods use a smaller cultivated fraction with plant ingredients, while Mission Barns and Mosa Meat have pursued cultivated fat as an ingredient. Licensing takes another route, offering cell lines, media, equipment designs or process know-how to other manufacturers.
These models put revenue in different places. A brand sells finished food to customers. An ingredient supplier sells fat or biomass to manufacturers. A technology licensor sells access to a process another operator must be able to reproduce. That changes which assets a company owns, whom it has to persuade and how an order reaches production.
The customer still has to enjoy the food
Taste and price can determine a second purchase after a first tasting driven by curiosity. Consumer studies also identify perceived safety, naturalness, animal welfare, environmental beliefs and familiarity with the process as factors in acceptance. Food neophobia and disgust can make an unfamiliar production method difficult to introduce. FSA’s review of consumer research.
The package name helps shape that response. “Lab-grown meat,” “cultivated meat” and “cell-cultured meat” can prompt different expectations. A manufacturer needs to explain the process and ingredients clearly while giving customers a food they can recognise, prepare and assess.
A survey can ask someone to respond to the idea of cultivated meat before they have eaten it. A tasting brings flavour and texture into that response. A restaurant also has to prepare and present the actual recipe. When a customer orders it again at the offered price, curiosity has become another purchase. Those steps help a manufacturer learn how a particular food fits its intended market.
A hybrid recipe brings its cultivated fraction and other ingredients onto the same package. Nutrition, animal-welfare and environmental claims have to describe that food. Composition data supports the nutritional account, and a life-cycle assessment follows the production route behind it. The manufacturer also has to make the ingredients and process understandable to the person buying dinner.
Growing from early products into regular supply
Regular supply brings the production and product choices together. A buyer ordering a fat ingredient needs it to perform in a recipe across deliveries. A restaurant needs the food when its menu requires it. A retail channel needs replenishment. The factory has to turn its process into that schedule.
At production scale, cell density and growth rate influence harvested output. Downstream processing turns that material into the amount that meets the food's specification. Failure rates and utilisation affect how often the line can deliver it. A series of runs connects those quantities to the dates a buyer can put into an order.
Media, utilities, labour, cleaning, testing, downtime and equipment enter the cost per kilogram at that operating rate. Tracking media cost and energy use per kilogram can locate losses between runs. Independent review can make the resulting figures easier for an outside buyer to use. Formulation remains in the calculation. A hybrid with a small cultivated fraction draws on different quantities of cell-derived material from a mostly cultivated food.
Repeat retail orders, restaurant distribution and ingredient contracts would connect that output to demand. Regulatory decisions in the EU, UK and Asia-Pacific will affect the available markets. Licensing deals and consolidation can move production among operators; legal outcomes for US state restrictions can change its sales destinations.
One possible route for expansion begins with premium products and jurisdictions where companies have a defined review pathway. Hybrid recipes and cultivated fat can put useful quantities into food while biomass costs continue to fall. Suppliers may standardise inputs and equipment, and manufacturers can use experience from repeated runs to support expansion into larger food-service and retail markets.
Thick whole cuts are likely to require more development. Commodity chicken and pork have particularly efficient conventional supply chains, so matching their prices may take longer. Expansion into those markets depends on production costs falling far enough to support the price and volume their buyers expect. This is a scenario for the industry's development, with the pace dependent on operating results and purchases.
For an ingredient supplier, a recurring contract could become a volume around which to schedule cultivation. The food manufacturer would plan its own batches against those deliveries. Expansion would have to keep those two schedules working together.